Combining JAK Inhibitors with Immune Checkpoint Inhibitors: Overcoming Resistance in Cancer Treatment

Hai-Jing Zhong

doi:10.1002/mco2.70141

MedComm ›› 2025, Vol. 6 ›› Issue (3) : e70141 DOI: 10.1002/mco2.70141

HIGHLIGHT

Combining JAK Inhibitors with Immune Checkpoint Inhibitors: Overcoming Resistance in Cancer Treatment

Hai-Jing Zhong ^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Hai-Jing Zhong. Combining JAK Inhibitors with Immune Checkpoint Inhibitors: Overcoming Resistance in Cancer Treatment. MedComm, 2025, 6(3): e70141 DOI:10.1002/mco2.70141

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	J. Zak, I. Pratumchai, B. S. Marro, et al., “JAK Inhibition Enhances Checkpoint Blockade Immunotherapy in Patients With Hodgkin lymphoma,” Science 384, no. 6702 (2024): eade8520.

[2]	D. Mathew, M. E. Marmarelis, C. Foley, et al., “Combined JAK Inhibition and PD-1 Immunotherapy for Non–small Cell Lung Cancer Patients,” Science 384, no. 6702 (2024): eadf1329.

[3]	D. P. McLornan, J. E. Pope, J. Gotlib, and C. N. Harrison, “Current and Future Status of JAK Inhibitors,” The Lancet 398, no. 10302 (2021): 803–816.

[4]	A. Haslam and V. Prasad, “Estimation of the Percentage of US Patients with Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs,” JAMA Network Open 2, no. 5 (2019): e192535–e192535.

[5]	M. A. Weniger and R. Küppers, “Molecular Biology of Hodgkin Lymphoma,” Leukemia 35, no. 4 (2021): 968–981.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.